Multi-platform molecular analysis of sarcomatoid renal cell carcinoma (sRCC)


Thai H. Ho, Sherri Z. Millis, Dave Bryant, Zoran Gatalica, Sandeep Reddy, Melissa L. Stanton, Eric P. Castle, Richard W. Joseph, Nicholas J. Vogelzang


Patients with sRCC have a have a poor prognosis and decreased likelihood of response to targeted therapy or IL-2. Predictive biomarkers of response are lacking in sRCC. We evaluated a cohort of RCC patients to identify potentially actionable recurrent molecular aberrations.

Download Publication